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similar genetic risk. These results certainly add to the already available in-
formation on lower rates of adherence to prophylactic measures in mi-
nority populations (Bradbury et al., 2008; Grimmer et al., 2015; Lynce
et al., 2015) but extend prior work by estimating reduction in cancer inci-The identiﬁcation of germline BRCA1 and BRCA2 (BRCA1/2)
underserved women is of paramount importance in an era where
population-wide screening for germline BRCA1/2mutations is being ac-mutations creates a unique opportunity to reduce the incidence of
breast and ovarian cancer by providing appropriate screening and risk
reducing prophylactic surgery options. Such downstream reductions
in cancer incidence will only be successful if identiﬁcation of a deleteri-
ous mutation is followed by prophylactic mastectomy and bilateral
salpingo-oophorectomy. The NCCN guidelines (v.2.2015) (National
Comprehensive Cancer Network inc., 2015) recommend that women
with deleterious BRCA1/2 mutations undergo breast screening with
annual breast MRI starting at the age 25, risk reducing salpingo-
oophorectomy (RRSO), typically between 35 and 40 years and upon
completion of child bearing, and discussion of risk-reducing mastecto-
my (RRM). Evaluation of the efﬁcacy of the prophylactic surgical
strategies has conﬁrmed a reduction in breast cancer with RRM of
approximately 90%, a reduction in ovarian cancer risk with RRSO of
85–90% and a reduction in breast cancer risk of 50%with premenopaus-
al RRSO. Additionally RRSO has been shown to reduce cancer speciﬁc
and all cause mortality in BRCA1/2 mutation carriers (Marchetti et al.,
2014). Thus, these prophylactic measures appear to reduce cancer
associated morbidity and mortality in BRCA1/2 mutation carriers,
although it is unclear whether the beneﬁt of RRSO is the same in
BRCA1 and in BRCA2mutation carriers (Domcheck et al., 2010).
In this issue of EBioMedicine, Robinson et al. (Robinson et al., 2015) are
to be commended for addressing interesting and important questions in
clinical genetics that include population-level screening in underserved
populations and the rate of adherence to risk reducing surgery recom-
mendations. Using a predictive model of cancer reduction in patients
with hereditary breast and ovarian cancer (HBOC) the authors estimated
an 8.8% reduction in breast and ovarian cancer in the underserved group




. This is an open access article underdence. Understanding the downstream effects of genetic testing among
tively discussed and advocated (King et al., 2014).
Theﬁndings by Robinson et al. provide an initial understanding of the
impact of population screening for HBOC through use of family history
assessment, navigation through genetic services and the offer of genetic
testing. Futurework can expandupon the results of Robinson et al. by ex-
tending the length of follow-up beyond 44months (mean 21months) as
prior work with primarily non-Hispanic White BRCA1/2 carriers has
demonstrated uptake of RRSO up to 7 years after receipt of a positive
BRCA result (Schwartz et al., 2012). Women of child-bearing age may
wait longer to undergo RRSO, while prophylactic mastectomies—again
documented primarily in non-Hispanic White women—appear to occur
largely within the ﬁrst year or two following testing (Schwartz et al.,
2012). The timing of prophylactic surgery among underserved women
is as yet unknown, and thus the results by Robinson et al. begin to shed
light on behavioral responses to genetic risk information among popula-
tions underrepresented in genetics research.
Expanding our awareness of additional factors that may inﬂuence
use of genetic services and adherence to NCCN recommendations
among underserved women at high risk for HBOC is a critical next
step. Even with navigation for genetic services, half of the women
from the safety net hospitals did not attend a scheduled appointment
(Robinson et al., 2015). Prior research denotes potential cultural, histor-
ical and attitudinal concerns as patient deterrents to genetic testing. As
uptake of genetic counseling and genetic testing is a personal and
value-based decision, it will be important to undertake future studies
with awareness that not all women at high risk may want to know or
act on this information (Halbert et al., 2012). Prominent issues such as
costs, lack of insurance, competing time or family demands may
contribute. As the Robinson study used predictive models to estimate
cancer risk reduction, individual level concerns like cost, fear or lack of
information could not be directly assessed.
In summary, Robinson et al. draw the attention to an important
theme of the use of genetic services and uptake of prophylactic
strategies in underserved populations. Future research can focus onthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1599F. Lynce, K. Graves / EBioMedicine 2 (2015) 1598–1599identifying barriers for such prophylactic strategies to develop effective
interventional trials. Additionally, better characterization of the
patterns of identiﬁcation and uptake of prophylactic approaches by
unaffected individuals with deleterious BRCA1/2 from underserved
and underrepresented populations is also urgently needed. With
signiﬁcant attention directed to precision medicine efforts, we must
continue to focus efforts on ways to identify, support and appropriately
manage cancer risk among the racially, ethnically and socioeconomically
diverse women with HBOC.
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